apixaban / Generic mfg. - LARVOL DELTA

ROXI-CAT-II: Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers (clinicaltrials.gov) - P3 | N=1600 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P3 trial • Cardiovascular • Hematological Malignancies • Oncology • Venous Thromboembolism

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Northern Jiangsu People's Hospital | Completed ➔ Recruiting

Enrollment open • Cardiovascular • Hematological Disorders • Hypertension • Immunology • Portal Hypertension • Thrombosis

BEYOND ANTICOAGULATION: PLEIOTROPIC EFFECTS OF APIXABAN IN NEPHROTIC SYNDROME AND PRIMARY GLOMERULONEPHRITIS (ISN-WCN 2026) - "Prophylactic anticoagulation is often advised, traditionally using warfarin, which has limitations such as dietary restrictions, drug interactions, need for INR monitoring, and bleeding risk. Moreover, apixaban reduced pro-inflammatory and pro-fibrotic cytokines, suggesting benefits beyond anticoagulation. These findings indicate potential renal and vascular protective effects of DOACs in glomerular diseases, warranting confirmation in larger randomized trials."

Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease • Venous Thromboembolism • IL6 • TGFB1 • TNFA

NON SURGICAL MANAGEMENT OF CATHETER RELATED ATRIAL THROMBI IN HAEMODIALYSIS PATIENTS : A CASE SERIES (ISN-WCN 2026) - "In three patients (37.5%), the catheter was salvaged.Conclusion In this case series, a conservative strategy with dose-adjusted Apixaban was associated with 100% thrombus resolution and an excellent safety profile for intermediate-sized CRAT in HD patients. This approach may represent a viable, non-invasive alternative to high-risk surgery, warranting further investigation in larger, prospective studies"

Clinical • Cardiovascular

APIXABAN AND SODIUM THIOSULFATE IN CALCIPHYLAXIS: UNEXPECTED SUCCESSFUL COMBINATION THERAPY (ISN-WCN 2026) - "Radiological investigations (CT-Scan) revealed extensive vascular and soft tissue calcifications, raising suspicion for Calciphylaxis.Download: Download high-res image (283KB)Download: Download full-size imageDownload: Download high-res image (285KB)Download: Download full-size imageDownload: Download high-res image (439KB)Download: Download full-size imageDownload: Download high-res image (347KB)Download: Download full-size imageBased on the disease's pathophysiology and the various contributing factors, the patient underwent multidisciplinary management, including optimization of hemodialysis with a low calcium bath, Extension of hemodialysis sessions thanks to the administration of analgesics such as morphine derivatives. We discontinued the treatments that potentially contributed to the progression of the disease, such as vitamin D, corticosteroid and Acenocoumarol and she underwent dozens hyperbaric oxygen therapy (HBOT)...Early recognition of risk factors and..."

Combination therapy • Calciphylaxis • Immunology • Inflammatory Arthritis • Lupus • Rare Diseases • Systemic Lupus Erythematosus

APIXABAN AND VASCULAR ACCESS THROMBOSIS IN DIALYSIS: A COMPARATIVE BEFORE-AND-AFTER ANALYSIS (ISN-WCN 2026) - "Bleeding occurred in 3.7% (95% CI 1.7–6.9%), none of whom required transfusion.Conclusion Apixaban therapy was associated with a significant reduction in recurrent AVF/G thrombosis and a low incidence of clinically significant bleeding, suggesting that apixaban may prolong access patency in patients on chronic hemodialysis. Rigorous randomized controlled trials may be required to confirm efficacy, define safety, and inform clinical practice guidelines for anticoagulation in this high-risk population."

Atrial Fibrillation • Cardiovascular • Hematological Disorders • Nephrology • Thrombosis • Venous Thromboembolism

COMPARATIVE OUTCOMES OF APIXABAN VERSUS WARFARIN INITIATION IN PATIENTS ON HEMODIALYSIS WITH NEWLY DIAGNOSED ATRIAL FIBRILLATION (ISN-WCN 2026) - "Dr. Chang has served on a Data Safety Monitoring Board for a trial by Bayer.I did not use generative AI and AI-assisted technologies in the writing process."

Clinical • Atrial Fibrillation • Cardiovascular • Cerebral Hemorrhage • Hematological Disorders • Infectious Disease • Ischemic stroke • Musculoskeletal Diseases • Myocardial Infarction • Orthopedics • Pneumonia • Pulmonary Embolism • Renal Disease • Respiratory Diseases

BEYOND CHADS2-VASC: QUESTIONING SYSTEMIC ANTICOAGULATION IN ADVANCED CHRONIC RENAL DISEASE WITH AURICULAR FIBRILATION (ISN-WCN 2026) - "Even the most recent clinical guidelines recommend individualized use of these scales in this subgroup of patients.Regarding treatment, vitamin K antagonist anticoagulants, such as warfarin or acenocoumarol, have historically been the most widely used drugs...In addition, INR control is especially complex in these patients, with increased risk of overanticoagulation.Direct-acting oral anticoagulants, such as apixaban, edoxaban, rivaroxaban and dabigatran, have demonstrated a better safety profile in certain contexts, with lower bleeding risk than vitamin K antagonist anticoagulants...This scale allows a stratification more adjusted to the renal profile and contributes to reduce unnecessary exposure to anticoagulant treatments with significant bleeding risk.It is necessary to promote a multidisciplinary and individualized approach in the assessment of thromboembolic and bleeding risk in this population, integrating the nephrologist in the therapeutic decision-making..."

Metastases • Atrial Fibrillation • Calciphylaxis • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Peripheral Arterial Disease • Pulmonary Arterial Hypertension • Rare Diseases • Renal Disease

ANTICOAGULANT - ASSOCIATED ACUTE KIDNEY INJURY: A PHARMACOVIGILANCE ANALYSIS BASED ON FDA ADVERSE EVENT REPORTING SYSTEM (ISN-WCN 2026) - "A).Warfarin had stable low reports, while newer oral anticoagulants (NOACs) showed dramatic trends: Apixaban peaked over 20,000 around 2021, Rivaroxaban near 20,000 in 2015, Dabigatran over 11,000 in 2012. Drugs like Argatroban, Bivalirudin, and Dalteparin had consistently low reports (Fig...Results show heterogeneity in renal ADRs; Fondaparinux and Apixaban signal specific toxicities. Findings can guide pharmacovigilance and clinical decisions for renal risk patients."

Adverse events • Acute Kidney Injury • Nephrology • Renal Disease • ROR1

Embedding Randomization in a National CKD Registry: The SACK Apixaban Study (ISN-WCN 2026) - No abstract available

Chronic Kidney Disease

Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials. (PubMed, Adv Ther) - "For example abelacimab, an anti-FXI monoclonal antibody, demonstrated superior safety with lower bleeding rates when compared to rivaroxaban in patients with AF...However, the OCEANIC-AF trial, which studied the small molecule FXI inhibitor asundexian, was terminated early due to lack of efficacy as there was an increased rate of stroke and systematic embolism compared to the DOAC apixaban, raising new concerns about the utility of targeting FXI. However, many FXI inhibitors are currently undergoing phase 3 trials, and as such the true efficacy of the full class of FXI inhibitors remains to be elucidated. This review aims to provide a comprehensive synopsis of the landscape of FXI inhibitors in development for AF, their advantages, challenges, and known utility with a focus on how they may be applied to future anticoagulation therapy for AF."

Journal • Review • Atrial Fibrillation • Cardiovascular

Discrepant Outcomes of Direct Oral Anticoagulant Trials in Device-Detected Atrial Fibrillation after Stroke: Insights from NOAH-AFNET 6 and ARTESIA. (PubMed, Clin Appl Thromb Hemost) - "In ARTESIA, apixaban was associated with a reduction in ischemic stroke accompanied by an increase in major bleeding, yielding a relatively coherent benefit-risk signal in this high-risk subgroup. In contrast, NOAH-AFNET 6 demonstrated a modest and statistically non-significant reduction in ischemic stroke alongside a substantial increase in major bleeding. Further research is still needed to refine patient selection and optimize therapeutic strategies."

Journal • Review • Atrial Fibrillation • Cardiovascular • Ischemic stroke

Safety and efficacy of apixaban versus enoxaparin in gynecologic cancer patients undergoing open surgery: an open-label randomized controlled trial. (PubMed, Thromb J) - "These findings support apixaban as a viable alternative to enoxaparin in this population. IRCT20220211053991N1."

Journal • Cardiovascular • Gynecologic Cancers • Oncology • Venous Thromboembolism

Analysis of the clinical characteristics of direct oral anticoagulants-associated atraumatic splenic rupture. (PubMed, Front Pharmacol) - "Among them, apixaban (n = 17) was the most common DOAC, followed by rivaroxaban (n = 8) and dabigatran (n = 2), with atrial fibrillation (81.5%, n = 22) being the primary indication. ASR is a potentially life-threatening but preventable DOAC complication. Early recognition-particularly in elderly patients with comorbidities and polypharmacy-and urgent imaging for abdominal pain are crucial for improving clinical outcomes."

Journal • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertension • Infectious Disease • Oncology • Pain

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Northern Jiangsu People's Hospital | Completed ➔ Recruiting

Enrollment open • Cardiovascular • Hematological Disorders • Hypertension • Immunology • Portal Hypertension • Thrombosis

Warfarin use: how many of you in CKD5D have stopped using it and now use Apixaban or Rivaroxaban (ERA 2026) - No abstract available

Cardiovascular • Chronic Kidney Disease

Advancing Point-of-Care Analysis: The Future of Thromboelastographic DOAC-Detection: A Systematic Review. (PubMed, Semin Thromb Hemost) - "For direct factor Xa inhibitors-rivaroxaban, apixaban, and edoxaban-modified assays using Russell's Viper Venom, factor Xa-based reagents, and low-tissue-factor activation showed variable but generally good correlations with drug levels (r = 0.571-0.969). Ecarin-based tests appear reliable for dabigatran, while Russell's Viper Venom and low-tissue-factor approaches may enable detection of direct factor Xa inhibitors. However, further clinical validation and standardization are required before routine implementation."

Journal • Cardiovascular • Ischemic stroke

Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers. (PubMed, Res Pract Thromb Haemost) - "Rivaroxaban and apixaban were used in 55% and 45% of patients, respectively. No deaths were attributed to thrombosis or anticoagulant-related bleeding. Rates of recurrent/progressive thrombosis and clinically relevant bleeding in our cohort of children with cancer-associated thrombosis are higher than those reported in previous studies, highlighting the importance of real-world data."

Journal • Real-world evidence • Cardiovascular • Hematological Disorders • Oncology • Oral Cancer • Pediatrics • Thrombosis • Venous Thromboembolism

DIAMOND: DIrect Oral Anticoagulation and Bioprothesis Aortic Valve (clinicaltrials.gov) - P3 | N=1500 | Recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Heart Failure

Unmasking a Culprit: A Case of Apixaban-Induced Subacute Cutaneous Lupus Erythematosus (AAD 2026) - No abstract available

Clinical • Cutaneous Lupus Erythematosus • Immunology • Inflammatory Arthritis • Lupus

Serial false lumen patency evaluation of a type B dissection represented with malperfusion following medical management. (PubMed, J Vasc Surg Cases Innov Tech) - "We report a 55-year-old man on apixaban for pulmonary embolism with a subacute zone 3-10L TBAD without malperfusion...Urgent endovascular repair was performed successfully. This case illustrates the unpredictable course of medically managed TBAD and need for judicious use of anticoagulation."

Journal • Back Pain • Cardiovascular • Hematological Disorders • Musculoskeletal Pain • Pain • Pulmonary Embolism • Respiratory Diseases

Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants. (PubMed, Front Pharmacol) - "In this real-world cohort, apixaban and rivaroxaban plasma concentrations were not associated with clinical outcomes. While highlighting the limitations of analyzing clinical outcomes within the framework of a pharmacokinetic study, these data are informative for future meta-analyses aimed at minimizing publication bias from neutral results."

Journal • PK/PD data • Cardiovascular • Ischemic stroke • Venous Thromboembolism

Safety of prothrombin complex concentrate for emergency surgery according to the oral factor Xa inhibitor level. (PubMed, Thromb Haemost) - "Results PCC at a median dose of 2000 units (interquartile range, 2000-2000) was administered to 227 patients on apixaban (143; 63%), rivaroxaban (72; 32%), or edoxaban (12;5%). Conclusion The risk of thromboembolism after 4F-PCC in patients on XaI and emergency surgery/invasive procedures appears to be similar among patients with preoperative XaI levels that are high, low or not measured. This information might be helpful in settings where rapid anti Xa testing is unavailable."

Journal • Cardiovascular • Venous Thromboembolism

Efficacy and Safety of DOACs in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: The Liverpool AF-Falls Project. A Systematic Review and Bayesian Network Meta-analysis. (PubMed, Drugs Aging) - "DOACs appear to have different efficacy and safety profiles and overall are preferable over VKAs in patients with AF with a history or risk of falls. Because of bias, further research is warranted."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular

Evaluating the incidence of thrombosis in patients with concurrent second-generation androgen receptor inhibitor therapy and direct oral anticoagulants: A retrospective chart review. (PubMed, J Oncol Pharm Pract) - "This study suggests that there is not an increased incidence of VTE or stroke when compared to historical controls. This study may help clinicians make risk benefit decisions regarding concurrent therapies."

Journal • Retrospective data • Cardiovascular • Genito-urinary Cancer • Hematological Disorders • Ischemic stroke • Oncology • Prostate Cancer • Pulmonary Embolism • Respiratory Diseases • Solid Tumor • Thrombosis